MENU
Advertisement
Show Filters
Refine by Content Type
Refine by Year
Sort By:
Choose Sites to Search:
Treatment Selection for Multivessel Coronary Artery Disease
A practical appraisal for selecting the best revascularization therapy for patients with multivessel CAD.
By Philippe Garot, MD, FESC, and Thierry Lefevre, MD, FESC, FSCAI
One-Year PARTNER EU Results Reported for High-Risk Patients Treated With Edwards Sapien Valve
December 1, 2010—One-year follow-up results of the multicenter PARTNER EU (European Placement of Aortic Transcatheter Valve Trial) study of transcatheter heart valve implantation (TAVI) have been published by Thierry Lefévre, MD, et al online ahead of print in the European Heart Journal.
Thirty-Day Results Presented at TCT for Direct Flow Medical's TAVR System
October 23, 2012—Direct Flow Medical, Inc. (Santa Rosa, CA) announced findings from its DISCOVER CE Mark trial at the TCT 2012: Transcatheter Cardiovascular Therapeutics conference in Miami, Florida.
Chief Medical Editor's Page
Optimal PCI in Contemporary Practice
By Ted E. Feldman, MD, FSCAI, Chief Medical Editor
BRAVO 3 Compares Bivalirudin to Heparin for TAVR
October 15, 2015—Results from the BRAVO 3 trial found that bivalirudin (Angiox, The Medicines Company) did not significantly reduce rates of major bleeding at 48 hours or adverse events at 30 days compared to heparin in high-risk patients undergoing transcatheter aortic valve replacement (TAVR).
